Taking on board higher near-term expenses
22/06/22 -"However, these expenses are investment into growth and should continue to support Astra’s sector-leading top-line growth in the coming years. Overall, our positive stock recommendation on the pharma ..."
Pages
64
Language
English
Published on
22/06/22
You may also be interested by these reports :
04/06/26
Over the 5 days to 02-06, 18 pharma stocks out of the 23 under coverage fell. The sector performance chart is not looking good. We see an opportunity ...
01/06/26
At a time when a lot of Big Pharmas are losing sleep because of looming patent expirations over the next five years, the likes of Sandoz (REDUCE; ...
30/05/26
With Sandoz being a pioneer and amongst the handful of firms with true biosimilar development capability, manufacturing expertise in complex ...
28/05/26
Backed by life cycle management of some of its key products, expansion into LatAm, a rebound of the animal healthcare business, and the recent ...